Clinical trial
Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and…
NCT00169104 · Dartmouth-Hitchcock Medical Center, Other · Terminated
Key facts
| NCT number | NCT00169104 |
|---|---|
| Title | Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function |
| Official title | A Phase II Trial of Trastuzumab, Neupogen, and Vinorelbine Investigating the Effects on Immune Function and Clinical Outcomes in Patients With Metastatic Breast Cancer Overexpressing Her-2/Neu |
| Lead sponsor | Dartmouth-Hitchcock Medical Center, Other |
| Collaborators | Amgen Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | G-CSF, trastuzumab, vinorelbine, saline placebo |
| Enrollment | 23 |
| Start date | Jul 1, 2002 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Sep 15, 2005 |
| Last update posted | Jul 20, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: